GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » FCF Margin %

Laekna (HKSE:02105) FCF Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Laekna FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Laekna's Free Cash Flow for the six months ended in Dec. 2024 was HK$-145.41 Mil. Laekna's Revenue for the six months ended in Dec. 2024 was HK$0.00 Mil. Therefore, Laekna's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Laekna's current FCF Yield % is -5.39%.

The historical rank and industry rank for Laekna's FCF Margin % or its related term are showing as below:


HKSE:02105's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -120.3
* Ranked among companies with meaningful FCF Margin % only.

Laekna FCF Margin % Historical Data

The historical data trend for Laekna's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna FCF Margin % Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23 Dec24
FCF Margin %
- - - -

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
FCF Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Laekna's FCF Margin %

For the Biotechnology subindustry, Laekna's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laekna's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Laekna's FCF Margin % falls into.


;
;

Laekna FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Laekna's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-299.178/0
= %

Laekna's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-145.413/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laekna FCF Margin % Related Terms

Thank you for viewing the detailed overview of Laekna's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » FCF Margin %
Comparable Companies
HKSE:02315 HKSE:02142 HKSE:02256 HKSE:00775 HKSE:06660 HKSE:02480 HKSE:02157 HKSE:06955 HKSE:02616 HKSE:01672 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
4U4:Germany
Address
No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203
Website
https://www.laekna.com
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Orbimed Advisors Iii Limited 2102 Investment manager
Orbimed Asia Gp Iii, L.p. 2102 Investment manager
Orbimed Asia Partners Iii, L.p. 2102 Investment manager
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Laekna Wonderland Limited 2101 Beneficial owner
Lu Chris Xiangyang 2501 Other
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Liu Zeng 2201 Interest of corporation controlled by you
Ealex Llc 2101 Beneficial owner
Futu Trustee Limited 2301 Trustee

Laekna Headlines

No Headlines